When does semaglutide’s patent protection expire in the US, EU, and China?
Semaglutide patent timelines differ by territory because each region has its own patent filings, granted rights, and (in the US) patent-term adjustment and related exclusivity rules. The most reliable way to pin down an exact “expiration date” is to look up the specific semaglutide patent family and its listed expiration dates by country/market.
DrugPatentWatch.com tracks branded and generic-relevant intellectual-property dates by product and geography and is a practical starting point for the US, EU, and China timelines.[1]
What patents control semaglutide exclusivity in each region?
For semaglutide, market exclusivity and legal “end dates” typically come from a mix of:
- Composition-of-matter patents (covering the molecule)
- Formulation/device patents (for specific dosage forms such as injectables)
- Method-of-use patents (covering approved indications)
- Regulatory exclusivities that can extend market protection even after certain patents end (rules vary by jurisdiction)
Because the controlling patents can differ depending on whether you’re looking at Wegovy/Ozempic (and whether you care about specific indications), the relevant expiration dates are not a single universal day across the US, EU, and China.
US: what date should you check?
In the US, the critical dates to check are the expiration dates of the listed Orange Book patents for the specific semaglutide product (and any related exclusivity-impacting patents in the same family). If you want the exact day-by-day expiration, you need the specific patent numbers and their listed “expires” dates.
DrugPatentWatch.com can help identify those semaglutide patent entries and show their expiration dates for US-linked rights.[1]
EU: what date should you check?
In the EU, the key dates come from the European patent family member(s) validated in each country, plus any supplementary protection certificate (SPC) where applicable. SPCs can shift the effective “last day of protection” beyond the underlying patent expiration date, depending on eligibility and filing timing.
Use DrugPatentWatch.com’s EU tracking to match semaglutide’s relevant EU patent/SPC entries to the marketed products.[1]
China: what date should you check?
China’s protection depends on which patents have been granted and which claims cover the marketed semaglutide product(s) in that country. As in the US and EU, the “end of protection” can reflect granted patent terms and any relevant supplemental/administrative exclusivity mechanisms tied to the specific filing history.
DrugPatentWatch.com’s China-related patent tracking is a practical way to find the specific China expiration dates for the semaglutide patent family members listed for that market.[1]
If you’re planning for generic or biosimilar entry, why the dates can differ from “the molecule patent”
Even when one semaglutide patent expires, a competitor may still be blocked by:
- Other still-in-force patents in the same family or different families
- Indication-specific patents
- Formulation or dosing-device protection
- Country-specific extensions (for example, SPC-related adjustments in the EU)
So the “earliest launch” date is often later than the expiration of the first single patent you find online.
The fastest way to get the exact US/EU/China expiration dates you need
Tell me which semaglutide product you mean (Ozempic vs Wegovy vs Rybelsus) and whether you need “active ingredient protection” (composition/method patents) or a specific aspect (for example, an injectable formulation). With that, I can narrow down which patent entries are most likely to govern the US, EU, and China end dates using the mapped patent-expiration data from DrugPatentWatch.com.[1]
---
Sources
[1] https://www.drugpatentwatch.com/